Stephen P Thorne

Author:

Stephen Thorne

ISBN #:

0754062511

US Patent:

D458905, Jun 18, 2002

Filed:

Mar 30, 2000

Appl. No.:

29/121190

Inventors:

Craig J. Jahne - Beaverton OR
Martin Lund - Hellerup, DK
Michael P. Colombo - Beaverton OR
Todd L. Smith - Hillsboro OR
Holly E. Bullins - Hillsboro OR
Ole L. Schioeler - Bagsvaerd, DK
Stephen P. Thorne - Beaverton OR
Richard T. Linton - Poway CA
Andrew J. Calkins - Hillsboro OR
Brian S. Yoshinaka - Aloha OR
Stephen L. Chenoweth - Portland OR
Stephen R. Brown - Portland OR
Steven M. Rodden - Sherwood OR
Chris A. Valentine - Portland OR

Assignee:

Intel Corporation - Santa Clara CA

International Classification:

1303

US Classification:

D13158

US Patent:

7687474, Mar 30, 2010

Filed:

Dec 20, 2006

Appl. No.:

11/643628

Inventors:

A. C. Matin - Stanford CA, US
Yoram Barak - Menlo Park CA, US
Susan V. Lynch - San Francisco CA, US
David F. Ackerley - Wellington, NZ
Stephen H. Thorne - Palo Alto CA, US
Christopher H. Contag - Stanford CA, US
Jianghong Rao - Palo Alto CA, US

Assignee:

The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA

International Classification:

A61K 48/00
C12N 5/00

US Classification:

514 44, 4353201

Abstract:

Compositions and methods are provided for the treatment of cancer.

US Patent:

20070077231, Apr 5, 2007

Filed:

Sep 29, 2006

Appl. No.:

11/529807

Inventors:

Christopher Contag - Stanford CA, US
Stephen Thorne - Stanford CA, US

International Classification:

A61K 48/00
C12N 5/08
C12N 15/86

US Classification:

424093200, 435456000, 435372000

Abstract:

Compositions and methods are provided for the treatment of cancer. An immune effector cell population is pre-infected with an oncolytic virus. The combined therapeutic is safe and highly effective, producing an enhanced anti-tumor effect compared to either therapy alone. The methods of the invention thus provide for a synergistic effect based on the combined biotherapeutics.

US Patent:

20110160146, Jun 30, 2011

Filed:

Feb 5, 2009

Appl. No.:

12/865692

Inventors:

Paul Wender - Menlo Park CA, US
Stephen H. Thorne - Pittsburgh PA, US
Christopher H. Contag - Stanford CA, US

Assignee:

National Institute of Health (NIH) - Bethesda MD

International Classification:

A61K 47/48
C12N 5/09
C12N 5/095
C07K 2/00
C07K 7/06
C07K 7/08
A61P 35/00

US Classification:

514 193, 435375, 530300, 530329, 530328, 530327

Abstract:

Many cancer therapeutic agents elicit resistance that renders them ineffective and often produces cross resistance to other drugs. One of the most common mechanisms of resistance involves P-glycoprotein (Pgp) mediated drug efflux. Here we provide compositions and methods that restore the efficacy of a therapeutic agent reduced by resistance by conjugation of the same agent to an oligoarginine transporter comprising from about 5 to about 25 guanidino or amidino moieties. We specifically show that the widely used chemotherapeutic agent taxol, ineffective against taxol-resistant human ovarian cancer cell lines, can be incorporated into an octaarginine conjugate that is effective against the same taxol-resistant cell lines. Significantly, the ability of the taxol conjugates to overcome taxol resistance is observed both in cell culture and in animal models of ovarian cancer. The generality and mechanistic basis for this effect were also explored with other Pgp substrate. This approach shows generality for overcoming the multidrug resistance elicited by small molecule cancer chemotherapeutics and could improve the prognosis for many cancer patients and fundamentally alter search strategies for novel therapeutic agents effective against resistant disease.

US Patent:

20130028875, Jan 31, 2013

Filed:

May 14, 2012

Appl. No.:

13/470558

Inventors:

Christopher H. Contag - Stanford CA, US
Stephen Thorne - Pittsburgh PA, US

International Classification:

A61K 35/76
A61P 35/00
C12N 5/10

US Classification:

424 9321, 4353723

Abstract:

Compositions and methods are provided for the treatment of cancer. An immune effector cell population is pre-infected with an oncolytic virus. The combined therapeutic is safe and highly effective, producing an enhanced anti-tumor effect compared to either therapy alone. The methods of the invention thus provide for a synergistic effect based on the combined biotherapeutics.